Brief: Molecular Templates Inc Says Restructuring To Reduce Workforce By About 50%, Result In Cessation Of MT-5111 (HER2) Clinical Development Program
30/03/2023 23:19
March 30 (Reuters) - Molecular Templates Inc MTEM.O :
* MOLECULAR TEMPLATES, INC. REPORTS FOURTH QUARTER 2022
FINANCIAL
RESULTS AND BUSINESS UPDATE
* MOLECULAR TEMPLATES INC - ANNOUNCED A STRATEGIC
REPRIORITIZATION
AND CORRESPONDING REDUCTION IN WORKFORCE
* MOLECULAR TEMPLATES INC - ON MARCH 29, BOARD OF DIRECTORS
OF
MTEM APPROVED A STRATEGIC REPRIORITIZATION AND CORRESPONDING
REDUCTION IN WORKFORCE
* MOLECULAR TEMPLATES INC - RESTRUCTURING TO REDUCE
WORKFORCE BY
ABOUT 50%, RESULT IN CESSATION OF MT-5111 (HER2) CLINICAL
DEVELOPMENT PROGRAM
* MOLECULAR TEMPLATES INC - QTRLY EARNINGS PER SHARE $0.39
Source text for Eikon: ID:nGNX4rn6lF
Further company coverage: MTEM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Molecular Templates
See all newsBrief: Molecular Templates Co & Affiliate Commenced Chapter 11 Cases As DIP
Brief: Molecular Templates's Eric E. Poma Resigns As CEO, CSO, Treasurer, And Interim CFO
Brief: Molecular Templates Announces Notice Of Delisting And Failure To Satisfy Continued Listing Rules
Brief: Molecular Templates Announces Receipt Of Expected Notification Of Deficiency From Nasdaq
Brief: Molecular Templates Approved Liquidation & Wind Up Through A Dissolution